The Verdict Is In: Teva Is Worth Buying

News | 03 July 2012

Though Teva is known mostly for its portfolio of generic drugs, Copaxone is ironically Teva's biggest-selling drug and it comes off patent in 2015. Rival generic-drug makers have been fighting to end the patent much sooner and launch their own lower ...

Click on the link to read the full article at Barron's
(This link will open in a new window)